Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?

S. Faderl; M. Talpaz; H. M. Kantarjian; Z. Estrov

doi:10.1182/blood.v93.9.2755.409a45_2755_2759

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?

S. Faderl, M. Talpaz, H. M. Kantarjian, Z. Estrov

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2755-2759
Number of pages	5
Journal	Blood
Volume	93
Issue number	9
DOIs	https://doi.org/10.1182/blood.v93.9.2755.409a45_2755_2759
State	Published - May 1 1999

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.v93.9.2755.409a45_2755_2759

Cite this

@article{248ae16d06d5426885ec13571f9dae83,

title = "Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?",

author = "S. Faderl and M. Talpaz and Kantarjian, {H. M.} and Z. Estrov",

year = "1999",

month = may,

day = "1",

doi = "10.1182/blood.v93.9.2755.409a45_2755_2759",

language = "English (US)",

volume = "93",

pages = "2755--2759",

journal = "Blood",

issn = "0006-4971",